Craig Hallum Begins Coverage on DiaMedica Therapeutics (NASDAQ:DMAC)

Craig Hallum assumed coverage on shares of DiaMedica Therapeutics (NASDAQ:DMAC) in a research report report published on Wednesday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $8.00 price objective on the stock.

Separately, Oppenheimer reaffirmed an outperform rating and set a $6.00 target price (down previously from $7.00) on shares of DiaMedica Therapeutics in a research report on Thursday, March 21st.

DiaMedica Therapeutics Stock Up 2.0 %

Shares of NASDAQ DMAC opened at $2.58 on Wednesday. The stock’s fifty day simple moving average is $2.79 and its two-hundred day simple moving average is $2.69. DiaMedica Therapeutics has a 12-month low of $1.53 and a 12-month high of $4.75.

DiaMedica Therapeutics (NASDAQ:DMAC) last announced its earnings results on Wednesday, March 20th. The company reported ($0.14) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.14). As a group, equities research analysts anticipate that DiaMedica Therapeutics will post -0.69 earnings per share for the current fiscal year.

Institutional Trading of DiaMedica Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Stonebridge Capital Advisors LLC purchased a new stake in shares of DiaMedica Therapeutics during the 3rd quarter valued at $52,000. Paragon Associates & Paragon Associates II Joint Venture lifted its holdings in shares of DiaMedica Therapeutics by 6.4% during the 4th quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 500,000 shares of the company’s stock valued at $1,420,000 after purchasing an additional 30,000 shares during the last quarter. Finally, Avantax Advisory Services Inc. purchased a new stake in shares of DiaMedica Therapeutics during the 4th quarter valued at $36,000. Hedge funds and other institutional investors own 10.12% of the company’s stock.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.